Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Relypsa: New Buy Recommendation on Relypsa (RLYP, Buy, $14.98)

Investment Thinking in Brief
I am beginning coverage of Relypsa (RLYP)†with a Buy recommendation. At this point in time, the stock…
Read more…

ZS Pharma: Astra Zeneca to Acquire ZS Pharma at $90 per Share-DARN (ZSPH, $90)

On Friday, November 9, 2015 Astra Zeneca entered into a definitive agreement to buy ZS Pharma in an all-cash tender…
Read more…

Initiation Report on ZS Pharma (ZSPH, Buy, $40.97, Subscribers only)

ZS Pharma Investment Thesis
The Hyperkalemia Market Opportunity is Huge; There Are No Good Current Drugs

The most important piece of the…
Read more…

Effective Treatment of Hyperkalemia Promises to be a Multi-billion Opportunity

Key Points

There are no effective treatment options for long term treatment of hyperkalemia (high potassium levels).
My research suggests that the…
Read more…